Metropolis Healthcare

Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment

Metropolis Healthcare posted a 13% rise in Q2FY26 net profit to ₹53 crore, driven by increased patient and test volumes, network expansion, and improved performance across regions

Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.

According to the company filing, it delivered a 23 per cent year-on-year (Y-o-Y) revenue growth at the consolidated level, driven by robust momentum in preventive health check-ups

Metropolis added that the move is expected to enhance productivity and drive overall profitability across its network of laboratories operating in the region

Technical charts show that Dixon Technologies, Kirloskar Oil Engines, Metropolis Healthcare and RHI Magnesita have witnessed a 'Golden Crossover', hence are likely to see upside in the near-term.

'Amazon's entry is through a partnership with Orange Health. It is more of a distribution through Amazon'

Despite trading in overbought territory Delhivery, Metropolis Health look poised for up to 19% further gains, while Usha Martin stock could dip 9%; suggest technical charts.

At 6:40 AM, GIFT Nifty futures were trading 90 points higher at 24,730 level, indicating a higher start.

Metropolis Q4 profit dips due to one-off costs from acquisitions; FY25 profit rises 13.4% on demand for preventive testing and strong B2C, B2B growth

With its third acquisition in recent times, Metropolis' Ameera Shah said the firm will make another deal this financial year

Under the agreement, Metropolis' wholly-owned subsidiary Metropolis Histoxpert Digital Services Pvt Ltd will acquire 100 per cent ownership of DAPIC

This is the second acquisition in the North India market this financial year; share of North market to grow from 8 per cent now to 18 per cent by end of FY26

The company in the quarter ended December 31, 2024, reported a 15.3 per cent rise in consolidated net profit to Rs 31 crore as compared to Rs 27 crore a year ago

On a sequential basis, the company's revenue declined by 7.7 per cent, while PAT also fell by 32.5 per cent

"The HPV test will be rolled out on February 4 to coincide with World Cancer Day," an official with Metropolis said

Metropolis Healthcare, Alembic Pharma and Tejas Networks are the other 3 stocks to witness a 'Death Cross' on the chart in recent days; technically this is a negative development for these stocks.

India has several venture-backed startups for whom the natural consequence is to have an exit, and between profitability and growth in the journey ahead, "we opted for the latter", Zoya Brar, founder of Core Diagnostics, which was recently acquired by Metropolis Healthcare, said. Metropolis Healthcare, one of India's leading diagnostics chains, acquired specialised diagnostics company Core Diagnostics for Rs 246.8 crore last month. "For an organisation to scale, it can either do it organically or inorganically. Since we have a number of venture-backed startups (in India), the natural consequence is, there needs to be an exit. And while IPOs are an option, they need a certain volume and scale before it makes sense. So we will continue to see consolidation," Brar told PTI. "Most importantly, incumbents like Metropolis need to constantly differentiate themselves to remain ahead of the competitive landscape and one simple way to do that is to acquire insurgents that have built an ...

Union Bank stock futures plunged nearly 8% on the back of 54% increase in OI. On the other hand, Dr. Lal Path Labs and Metropolis Health witnessed long build-up on Monday; shows derivatives data.

Market share gains in the B2C portfolio are visible and Tier III+ markets are likely to contribute to the patient volume growth guidance